Title
Subscribe to the Magazine for free
Subscribe for free to keep reading! If you are already subscribed, enter your email address to log back in.
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Are you a healthcare practitioner?
Thanks for subscribing!
Oops! Something went wrong while submitting the form.

10 Lab Tests for Patients With a Family History of Heart Disease

Why This Was Updated?

Our specialists regularly review advancements in health and wellness, ensuring our articles are updated with the newest information as it becomes accessible.
Medically Reviewed by

Heart disease encompasses a range of cardiovascular conditions, including coronary artery disease, heart failure, arrhythmias, and valvular heart disease. According to the World Health Organization (WHO), it is the leading cause of mortality globally, responsible for approximately 17.9 million deaths annually.

Individuals with a family history of heart disease are at a heightened risk of developing these conditions. This elevated risk necessitates more stringent screening protocols as part of a preventive healthcare model for early detection and management.

Sign Up to Order Labs for Your Patients with a Family History of Heart Disease

[signup]

What Is Heart Disease?

Heart disease refers to various conditions that affect the heart's structure and function. Major types include:

  • Coronary Artery Disease (CAD): Narrowing or blockage of the coronary arteries, leading to reduced blood flow to the heart muscle.
  • Heart Failure: A condition where the heart cannot pump blood effectively to meet the body's needs.
  • Arrhythmias: Irregular heartbeats that can affect the heart's ability to function correctly.
  • Valvular Heart Disease: Dysfunction of one or more heart valves, affecting blood flow within the heart.

Heart disease remains the leading cause of death worldwide. In the United States alone, CAD accounts for about one in every four deaths. (8) Cardiovascular disease (CVD) prevalence is increasing due to factors like aging populations and lifestyle habits.

Relationship Between Family History and Heart Disease

Family history is a significant risk factor for heart disease. For example, a family history of myocardial infarction (MI) (heart attack) in first-degree relatives significantly increases the risk of MI. Specifically, having one, two, or three or more first-degree relatives with a history of MI increases the risk by 1.46, 2.38, and 3.58 times, respectively. This risk is also elevated, though to a lesser extent, with a history of MI in second-degree relatives. (58)Β 

The American College of Cardiology and the American Heart Association emphasize the importance of family history in assessing cardiovascular risk, noting that a family history of premature coronary heart disease (CHD) is an independent risk factor for future CVD. (36)Β 

Genetic predispositions play a role in the relationship between family history and heart disease. Inherited genetic mutations and polymorphisms can contribute to abnormalities in lipid metabolism and blood pressure regulation. Familial hypercholesterolemia (FH) is a prime example, where mutations in genes such as LDLR, APOB, and PCSK9 result in elevated low-density lipoprotein cholesterol (LDL-C) levels, increasing the risk for atherosclerosis and heart disease.

Importance of Lab Testing in High-Risk Patients

Early detection of cardiovascular risk factors through lab testing is critical for preventive care. Identifying risk factors before clinical symptoms emerge allows for timely interventions, such as implementing lifestyle changes and pharmacological treatments to reduce risk (75).Β 

Regular lab tests also help monitor disease progression and the effectiveness of interventions, facilitating personalized treatment adjustments. Lab results provide critical data for informed decision-making, aiding in the selection of appropriate preventive and therapeutic strategies and helping to stratify patients into different risk levels for tailored management.

Top 10 Lab Tests for Patients With Family History of Heart Disease

When detecting and stratifying risk for heart disease, healthcare providers should consider monitoring the following parameters:Β 

1. Lipid Profile

A lipid panel measures various types of lipid (fat) particles in circulation, including:

  • Total cholesterol (TC)
  • Low-density lipoprotein cholesterol (LDL-C)
  • High-density lipoprotein cholesterol (HDL-C)
  • Triglycerides (TG)Β 

Dyslipidemia (abnormal concentrations of lipids in the blood) is a significant risk factor for atherosclerosis and CAD.Β 

According to medical guidelines, optimal lipid levels are:

  • TC: 100-199 mg/dL
  • LDL-C: <70 mg/dL (very high risk for heart disease), <100 mg/dL (more than one risk factor for heart disease), <130 mg/dL (low risk of CAD)
  • HDL-C: >40 mg/dL (assigned male at birth) and >50 mg/dL (assigned female at birth)
  • TG: <150 mg/dLΒ 

More recent research has highlighted the importance of advanced lipid biomarkers to more accurately stratify cardiovascular risk beyond what traditional lipid markers can provide.Β 

Advanced lipid panels include additional markers that capture the atherogenicity of lipid particles in circulation:

LDL Particle Number (LDL-P)

The concentration of LDL particles in the blood. Elevated LDL-P is strongly associated with increased CVD risk, as it better reflects the number of atherogenic particles that can penetrate the arterial wall and contribute to atherosclerosis, compared to LDL-C. (57).

Optimal levels of LDL-P are generally considered to be below 1,100 nmol/L. (7)

Lipoprotein(a) [Lp(a)]Β 

A low-density lipoprotein-like particle bound to apolipoprotein(a). Elevated Lp(a) levels are an independent and genetically determined risk factor for CVD, contributing to atherogenesis, inflammation, and blood clots. (72)Β 

Optimal levels of Lp(a) are generally considered to be below 30 mg/dL, with levels above 50 mg/dL associated with increased CVD risk. (72)Β 

Apolipoprotein B (ApoB)Β 

A protein found in all atherogenic lipoproteins. Elevated ApoB levels are strongly associated with increased CVD risk because they reflect the total number of atherogenic particles, which are more predictive of atherosclerotic risk than LDL-C alone. (67)Β 

The National Lipid Association recommends that optimal levels of ApoB be below 90 mg/dL for primary prevention and below 80 mg/dL for those at very high risk (6).Β 

2. High-Sensitivity C-Reactive Protein (hs-CRP)

Elevated hs-CRP levels are associated with increased vascular inflammation and a higher risk of heart disease, as inflammation is central to promoting plaque formation and instability (60).Β 

hs-CRP levels can help predict the future risk of cardiovascular events:

  • Low Risk: <1 mg/L
  • Average Risk: 1-3 mg/L
  • High Risk: >3 mg/L

Research, such as the JUPITER trial, has demonstrated that patients with elevated hs-CRP (>2 mg/L) benefit significantly from statin therapy, reducing the rate of first MI, stroke, or cardiovascular death by 47%.

3. Hemoglobin A1c (HbA1c)

Diabetes is a significant risk factor for heart disease due to its association with high blood sugar (hyperglycemia), insulin resistance, and inflammation, which contribute to atherosclerosis and cardiovascular complications.Β 

HbA1c is a marker used to monitor long-term blood sugar control and diagnose diabetes, reflecting average blood glucose levels over the past 2-3 months. Reference ranges for HbA1c include:Β 

  • Normal: less than 5.7%
  • Prediabetes: 5.7% to 6.4%
  • Diabetes: 6.5% or higher

Research has shown that higher HbA1c levels correlate with an increased CVD risk. For instance, a study found that each 1% increase in HbA1c was associated with a 1.26-fold increased risk of CHD among diabetic patients.Β 

Another study demonstrated that elevated HbA1c levels were independently associated with cardiovascular mortality and CVD incidence in the general population.Β 

Optimal HbA1c levels for reducing CVD risk are generally considered to be below 7% for most adults with diabetes, as recommended by the American Diabetes Association.

4. Complete Blood Count (CBC)

A CBC is a comprehensive blood test that measures various components of the blood, including red blood cells (RBCs), white blood cells, and platelets. It is instrumental in diagnosing blood conditions such as anemia (low RBC count) and erythrocytosis (high RBC count) by evaluating RBC count and characteristics.

Research has shown that anemia is associated with increased CVD risk due to reduced oxygen-carrying capacity and RBC dysfunction, which can lead to adverse outcomes such as heart failure and MI.Β 

Conversely, erythrocytosis can increase blood viscosity, contributing to hypertension (high blood pressure) and atherosclerosis, thereby exacerbating heart disease (29).Β Β 

Elevated RDW, a parameter of RBC variability, has been linked to poorer outcomes in heart failure and other cardiovascular conditions.

5. Comprehensive Metabolic Panel (CMP)

A CMP is a blood test that evaluates various body functions and processes, including liver and kidney health, blood sugar levels, blood protein levels, acid-base balance, fluid and electrolyte balance, and metabolism.Β 

Key parameters related to cardiovascular health to monitor include:

  • Blood Glucose: Elevated blood sugar levels can indicate prediabetes or diabetes. High blood sugar is a risk factor for CVD because it can damage the heart's blood vessels and nerves. (79)Β 
  • Electrolytes: Imbalances in electrolytes, such as sodium and potassium, can affect heart function and blood pressure regulation.
  • Kidney Function: Elevated renal function tests (e.g., creatinine and blood urea nitrogen) indicate kidney dysfunction, which is associated with increased cardiovascular risk (64).Β 
  • Liver Enzymes: Abnormal levels in ALT, AST, and ALP can indicate liver disease, which is associated with a two-fold greater incidence of CVD.

6. Ferritin

Ferritin is a protein that stores iron and releases it in a controlled fashion, making it the primary marker for assessing iron stores in the body.Β 

Research has shown that iron deficiency is associated with worse outcomes in heart failure due to impaired mitochondrial function and reduced contractility of heart muscle cells (43).Β Β 

Conversely, iron overload can lead to oxidative stress, fibrosis, and cardiomyopathy, as seen in conditions like hereditary hemochromatosis and transfusion-related iron overload. According to one study, long-term elevations in ferritin (>2,500 ΞΌg/L) are linked to increased cardiac risk.

7. Thyroid Panel

A thyroid panel assesses thyroid function and typically includes measurements of thyroid-stimulating hormone (TSH), free thyroxine (fT4), and free triiodothyronine (fT3). These components help diagnose and monitor thyroid disorders.

Hypothyroidism is associated with increased CVD risk due to mechanisms like dyslipidemia, hypertension, and endothelial dysfunction (80). Research indicates that subclinical hypothyroidism (elevated TSH with normal fT4) is linked to increased CHD mortality and heart failure events, particularly when TSH levels are β‰₯10 mIU/L.

Hyperthyroidism, on the other hand, is associated with an increased risk of atrial fibrillation (AF). Studies have shown that subclinical hyperthyroidism (low or undetectable TSH with normal fT4) increases the risk of AF and CHD events, especially when TSH levels are <0.1 mIU/L.Β 

8. Homocysteine

Homocysteine is a sulfur-containing amino acid derived from the metabolism of methionine. Elevated homocysteine is associated with an increased risk of CVD due to its role in endothelial dysfunction, oxidative stress, atherogenesis, and blood clotting.

Ordering a homocysteine test for someone with a family history of heart disease can help identify hyperhomocysteinemia (levels greater than 15 Β΅mol/L).

9. Vitamin DΒ 

Vitamin D deficiency has been linked to increased CVD risk. Studies have correlated vitamin D deficiency with an increased risk of MI, hypertension, heart failure, and stroke.

Vitamin D deficiency also worsens health outcomes in patients with established CVD; in one study, patients with severe vitamin D deficiency (serum 25-hydroxyvitamin D [25(OH)D] <10 ng/mL) were up to five times more likely to die from sudden cardiac death or heart failure during a 7-year study period compared to patients who were vitamin D-sufficient.Β 

While vitamin D sufficiency is defined as 25(OH)D levels >30 ng/mL, studies suggest that 25(OH)D levels 40-60 ng/mL are optimal for CVD prevention (50).Β 

10. Urine Albumin-Creatinine Ratio (uACR)

uACR is a test that detects a protein called albumin in the urine. Normally, kidneys do not filter albumin out of the blood and into the urine. Microalbuminuria (small amounts of protein in the urine) indicates kidney dysfunction and strongly predicts heart disease.

Optimal uACR levels are considered to be <30 mg/g. However, research has indicated that elevated uACR levels, even within the normal range, increase the risk of all-cause mortality, cardiovascular mortality, and CAD. For instance, a meta-analysis found that individuals with uACR between 10-30 mg/g had a higher risk of cardiovascular events compared to those with uACR <10 mg/g.

[signup]

Key Takeaways

  • Proactive management is essential to mitigate the heightened risk of developing cardiovascular conditions in patients with a family history of heart disease.Β 
  • Regular lab testing is crucial in detecting and managing modifiable risk factors for heart disease, such as dyslipidemia, hypertension, diabetes, and inflammation. By incorporating comprehensive assessments – including advanced lipid profiles, hs-CRP, HbA1c, CBC, CMP, thyroid function tests, homocysteine, and vitamin D levels – healthcare providers can identify at-risk individuals before the onset of clinical symptoms.
  • Early interventions guided by lab results can significantly reduce the likelihood of adverse cardiovascular events.
The information provided is not intended to be a substitute for professional medical advice. Always consult with your doctor or other qualified healthcare provider before taking any dietary supplement or making any changes to your diet or exercise routine.
Learn More
No items found.

Lab Tests in This Article

No lab tests!

References

  1. Achuff, J. (2024, February 5). How to test and interpret total cholesterol levels: A functional medicine perspective. Rupa Health. https://www.rupahealth.com/post/how-to-test-and-interpret-total-cholesterol-levels-a-functional-medicine-perspective
  2. Achuff, J. (2024, February 6). How to lower your patient's triglycerides using root cause medicine. Rupa Health. https://www.rupahealth.com/post/how-to-lower-your-patients-triglycerides-using-root-cause-medicine
  3. Addisu, B., Bekele, S., Wube, T. B., et al. (2023). Dyslipidemia and its associated factors among adult cardiac patients at Ambo university referral hospital, Oromia region, west Ethiopia. BMC Cardiovascular Disorders, 23(1). https://doi.org/10.1186/s12872-023-03348-y
  4. American Diabetes Association Professional Practice Committee. (2021). 6. Glycemic Targets: Standards of Medical Care in Diabetesβ€”2022. Diabetes Care, 45(1), S83–S96. https://doi.org/10.2337/dc22-S006
  5. Baumgartner, C., da Costa, B. R., Collet, T.-H., et al. (2017). Thyroid Function Within the Normal Range, Subclinical Hypothyroidism, and the Risk of Atrial Fibrillation. Circulation, 136(22), 2100–2116. https://doi.org/10.1161/CIRCULATIONAHA.117.028753
  6. Bays, H. E., Jones, P. H., Brown, W. V., et al. (2014). National Lipid Association Annual Summary of Clinical Lipidology 2015. Journal of Clinical Lipidology, 8(6), S1–S36. https://doi.org/10.1016/j.jacl.2014.10.002
  7. Bowden, R. G., Wilson, R. L., & Beaujean, A. A. (2011). LDL particle size and number compared with LDL cholesterol and risk categorization in end-stage renal disease patients. Journal of Nephrology, 24(6), 771–777. https://doi.org/10.5301/jn.2011.6376
  8. Brown, J. C., Gerhardt, T. E., & Kwon, E. (2023, January 23). Risk Factors For Coronary Artery Disease. PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK554410/
  9. Chacko, M., Sarma, P. S., Harikrishnan, S., et al. (2020). Family history of cardiovascular disease and risk of premature coronary heart disease: A matched case-control study. Wellcome Open Research, 5(5), 70. https://doi.org/10.12688/wellcomeopenres.15829.2
  10. Christie, J. (2022, March 8). Weakness, Pale Skin, And Headache Are Signs Of This Mineral Deficiency. Rupa Health. https://www.rupahealth.com/post/a-functional-medicine-approach-to-iron-deficiency
  11. Classes and Stages of Heart Failure. (2023, June 7). American Heart Association. https://www.heart.org/en/health-topics/heart-failure/what-is-heart-failure/classes-of-heart-failure
  12. Cloyd, J. (2022, November 17). Subclinical hypothyroidism: Signs, symptoms, & treatments. Rupa Health. https://www.rupahealth.com/post/subclinical-hypothyroidism-signs-symptoms-treatments
  13. Cloyd, J. (2023, February 1). 6 anemia types you need to know about. Rupa Health. https://www.rupahealth.com/post/6-different-types-of-anemia-you-may-not-be-aware-of
  14. Cloyd, J. (2023, May 1). A Functional Medicine Protocol for Coronary Artery Disease. Rupa Health. https://www.rupahealth.com/post/a-functional-medicine-protocol-for-coronary-artery-disease
  15. Cloyd, J. (2023, August 21). Thyroid Hormone Testing Guide: A Comprehensive Review of How to Test for Thyroid Hormones. Rupa Health. https://www.rupahealth.com/post/thyroid-hormone-testing-guide-a-comprehensive-review-of-how-to-test-for-thyroid-hormones
  16. Cloyd, J. (2023, October 9). Rhythms of the Heart: Demystifying Common Types of Heart Arrhythmia. Rupa Health. https://www.rupahealth.com/post/rhythms-of-the-heart-demystifying-common-types-of-heart-arrhythmia
  17. Cloyd, J. (2023, December 1). How to Interpret CBC Results: A Comprehensive Guide. Rupa Health. https://www.rupahealth.com/post/how-to-interpret-cbc-results-a-comprehensive-guide
  18. Cloyd, J. (2023, December 5). Inflammation and Heart Disease: A Functional Medicine Approach to Prevention and Treatment. Rupa Health. https://www.rupahealth.com/post/inflammation-and-heart-disease-a-functional-medicine-approach-to-prevention-and-treatment
  19. Cloyd, J. (2023, December 11). How to Interpret Your CRP Blood Test. Rupa Health. https://www.rupahealth.com/post/how-to-interpret-your-crp-blood-test
  20. Cloyd, J. (2023, December 26). How to Interpret An HbA1c Test and What it Means For Your Patient's Health. Rupa Health. https://www.rupahealth.com/post/how-to-interpret-an-hba1c-test-and-what-it-means-for-your-patients-health
  21. Cloyd, J. (2024, January 19). Understanding the Role of Kidney Function Tests in Comprehensive Health Assessments. Rupa Health. https://www.rupahealth.com/post/understanding-the-role-of-kidney-function-tests-in-comprehensive-health-assessments
  22. Cloyd, J. (2024, January 22). Interpreting Liver Enzyme Tests: ALT, AST, and ALP in Liver Health Monitoring. Rupa Health. https://www.rupahealth.com/post/interpreting-liver-enzyme-tests-alt-ast-and-alp-in-liver-health-monitoring
  23. Cloyd, J. (2024, March 5). How to lower LDL cholesterol naturally: Evidence-Based recommendations. Rupa Health. https://www.rupahealth.com/post/how-to-lower-ldl-cholesterol-naturally-evidence-based-recommendations
  24. Cloyd, J. (2024, March 6). How to Increase HDL Cholesterol: A Root Cause Medicine Approach. Rupa Health. https://www.rupahealth.com/post/how-to-increase-hdl-cholesterol-a-root-cause-medicine-approach
  25. Cloyd, J. (2024, March 13). The Genetic Basis of Familial Hypercholesterolemia and Its Clinical Implications. Rupa Health. https://www.rupahealth.com/post/the-genetic-basis-of-familial-hypercholesterolemia-and-its-clinical-implications
  26. Cloyd, J. (2024, September 10). High Protein in Urine Explained: What It Means and How to Manage It. Rupa Health. https://www.rupahealth.com/post/high-protein-in-urine-explained-what-it-means-and-how-to-manage-it
  27. Cloyd, J. (2024, September 13). Your Guide to Hyperglycemia (High Blood Sugar): Causes, Symptoms, Diagnosis, and Treatment Options. Rupa Health. https://www.rupahealth.com/post/your-guide-to-hyperglycemia-high-blood-sugar-causes-symptoms-diagnosis-and-treatment-options
  28. Cloyd, K. (2023, December 19). How to interpret your lipid panel results. Rupa Health. https://www.rupahealth.com/post/how-to-interpret-your-lipid-panel-results
  29. Corante, N., Anza-RamΓ­rez, C., Figueroa-MujΓ­ca, R., et al. (2018). Excessive Erythrocytosis and Cardiovascular Risk in Andean Highlanders. High Altitude Medicine & Biology, 19(3), 221–231. https://doi.org/10.1089/ham.2017.0123
  30. Daglis, S. (2024, March 7). Emerging Biomarkers for Lipid Disorders: Beyond Traditional Lipid Profiles. Rupa Health. https://www.rupahealth.com/post/emerging-biomarkers-for-lipid-disorders-beyond-traditional-lipid-profiles
  31. Daglis, S. (2024, August 16). High RBC Count Explained: What It Means and What to Do Next. Rupa Health. https://www.rupahealth.com/post/high-rbc-count-explained-what-it-means-and-what-to-do-next
  32. Danese, E., Lippi, G., & Montagnana, M. (2015). Red blood cell distribution width and cardiovascular diseases. Journal of Thoracic Disease, 7(10), E402–E411. https://doi.org/10.3978/j.issn.2072-1439.2015.10.04
  33. de Oliveira, L. B., de Figueiredo Martins Siqueira, M. A., de Macedo GadΓͺlha, R. B., et al. (2024). Vitamin D Deficiency in Patients Hospitalized for Heart Failure Living in the Tropics. International Journal of Heart Failure, 6(2), 84–90. https://doi.org/10.36628/ijhf.2023.0025
  34. DePorto, T. (2022, December 9). Functional Medicine Lab Tests for Heart Disease. Rupa Health. https://www.rupahealth.com/post/worried-about-heart-disease-ask-your-provider-for-these-6-specialty-labs-at-your-next-appointment
  35. DePorto, T. (2023, January 5). Electrolytes Imbalance: Symptoms & How to Treat It. Rupa Health. https://www.rupahealth.com/post/electrolytes
  36. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents, & National Heart, Lung, and Blood Institute. (2011). Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: Summary Report. PEDIATRICS, 128(Supplement), S213–S256. https://doi.org/10.1542/peds.2009-2107c
  37. Forman, J. P., Giovannucci, E., Holmes, M. D., et al. (2007). Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. Hypertension, 49(5), 1063–1069. https://doi.org/10.1161/HYPERTENSIONAHA.107.087288
  38. Fu, J., Sun, J., & Zhang, C. (2022). Vitamin D supplementation and risk of stroke: A meta-analysis of randomized controlled trials. Front. Neurol., 13. https://doi.org/10.3389/fneur.2022.970111
  39. Gammella, E., Recalcati, S., Rybinska, I., et al. (2015). Iron-Induced Damage in Cardiomyopathy: Oxidative-Dependent and Independent Mechanisms. Oxidative Medicine and Cellular Longevity, 2015, 1–10. https://doi.org/10.1155/2015/230182
  40. Giovannucci, E. (2008). 25-Hydroxyvitamin D and Risk of Myocardial Infarction in Men. Archives of Internal Medicine, 168(11), 1174. https://doi.org/10.1001/archinte.168.11.1174
  41. Hajar, R. (2020). Genetics in Cardiovascular Disease. Heart Views, 21(1), 55–56. https://doi.org/10.4103/heartviews.heartviews_140_19
  42. Henry, E. (2021, September 29). Are Your Patients Insulin Resistant? 4 Ways To Test. Rupa Health. https://www.rupahealth.com/post/insulin-resistance-testing
  43. Hoes, M. F., Grote Beverborg, N., Kijlstra, J. D., et al. (2018). Iron deficiency impairs contractility of human cardiomyocytes through decreased mitochondrial function. European Journal of Heart Failure, 20(5), 910–919. https://doi.org/10.1002/ejhf.1154
  44. Jayaprasad , N., & Johnson, F. (2005). Atrial Fibrillation and Hyperthyroidism. Indian Pacing and Electrophysiology Journal, 5(4), 305. https://pmc.ncbi.nlm.nih.gov/articles/PMC1431605/
  45. Khakham, C. (2023, April 6). Understanding Your Risk of Cardiovascular Disease With Functional Medicine Labs. Rupa Health. https://www.rupahealth.com/post/understanding-your-risk-of-cardiovascular-disease-with-functional-medicine-labs
  46. Khakham, C. (2023, June 1). Try These 10 Game-Changing Supplements To Support Your Heart Health. Rupa Health. https://www.rupahealth.com/post/integrative-cardiology-lifestyle-and-natural-approaches-to-heart-health
  47. Kirk, P., Roughton, M., Porter, J. B., et al. (2009). Cardiac T2* Magnetic Resonance for Prediction of Cardiac Complications in Thalassemia Major. Circulation, 120(20), 1961–1968. https://doi.org/10.1161/circulationaha.109.874487
  48. Lin, X., Chen, X., Liu, S., et al. (2023). Associations of Serum 25(OH)D With Risk of Recurrent Cardiovascular Events in Individuals With Coronary Heart Disease. The Journal of Clinical Endocrinology & Metabolism, 108(12), e1712–e1719. https://doi.org/10.1210/clinem/dgad339
  49. Lip, S., & Padmanabhan, S. (2020). Genomics of Blood Pressure and Hypertension: Extending the Mosaic Theory Toward Stratification. Canadian Journal of Cardiology, 36(5), 694–705. https://doi.org/10.1016/j.cjca.2020.03.001
  50. Lugg, S. T., Howells, P. A., & Thickett, D. R. (2015). Optimal Vitamin D Supplementation Levels for Cardiovascular Disease Protection. Disease Markers, 2015, 1–10. https://doi.org/10.1155/2015/864370
  51. Magerman, R. (2024, June 27). How to Use Advanced Lipid Testing to Assess Your Cardiac Risk. Rupa Health. https://www.rupahealth.com/post/advanced-lipid-testing-cardiac-risk
  52. Miller, R. L., Anderson, S. J., Costacou, T., et al. (2018). Hemoglobin A1c Level and Cardiovascular Disease Incidence in Persons With Type 1 Diabetes: An Application of Joint Modeling of Longitudinal and Time-to-Event Data in the Pittsburgh Epidemiology of Diabetes Complications Study. American Journal of Epidemiology, 187(7), 1520–1529. https://doi.org/10.1093/aje/kwx386
  53. Neibling, K. (2023, March 20). Health Problems Linked to Vitamin D Deficiency. Rupa Health. https://www.rupahealth.com/post/health-problems-linked-to-vitamin-d-deficiency
  54. Pereira, A. A., & Sarnak, M. J. (2003). Anemia as a risk factor for cardiovascular disease. Kidney International, 64, S32–S39. https://doi.org/10.1046/j.1523-1755.64.s87.6.x
  55. Pilz, S., März, W., Wellnitz, B., et al. (2008). Association of Vitamin D Deficiency with Heart Failure and Sudden Cardiac Death in a Large Cross-Sectional Study of Patients Referred for Coronary Angiography. The Journal of Clinical Endocrinology & Metabolism, 93(10), 3927–3935. https://doi.org/10.1210/jc.2008-0784
  56. Population shifts, risk factors may triple U.S. cardiovascular disease costs by 2050. (2024, June 4). American Heart Association. https://newsroom.heart.org/news/population-shifts-risk-factors-may-triple-u-s-cardiovascular-disease-costs-by-2050
  57. Qiao, Y.-N., Zou, Y.-L., & Guo, S.-D. (2022). Low-density lipoprotein particles in atherosclerosis. Frontiers in Physiology, 13. https://doi.org/10.3389/fphys.2022.931931
  58. Ranthe, M. F., Petersen, J. A., Bundgaard, H., et al. (2015). A Detailed Family History of Myocardial Infarction and Risk of Myocardial Infarction – A Nationwide Cohort Study. PLOS ONE, 10(5), e0125896. https://doi.org/10.1371/journal.pone.0125896
  59. Ren, F., Li, M., Xu, H., et al. (2021). Urine albumin‐to‐creatinine ratio within the normal range and risk of hypertension in the general population: A meta‐analysis. The Journal of Clinical Hypertension, 23(7), 1284–1290. https://doi.org/10.1111/jch.14263
  60. Ridker, P. M. (2016). A Test in Context: High-Sensitivity C-Reactive Protein. Journal of the American College of Cardiology, 67(6), 712–723. https://doi.org/10.1016/j.jacc.2015.11.037
  61. Ridker, P. M., Danielson, E., Fonseca, F. A. H., et al. (2008). Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. The New England Journal of Medicine, 359(21), 2195–2207. https://doi.org/10.1056/NEJMoa0807646
  62. Robinson, K. (2024, June 28). Living Well with Hemochromatosis: Understanding and Managing Iron Overload. Rupa Health. https://www.rupahealth.com/post/living-well-with-hemochromatosis-understanding-and-managing-iron-overload
  63. Roca-Fernandez, A., Banerjee, R., Thomaides-Brears, H., et al. (2023). Liver disease is a significant risk factor for cardiovascular outcomes – A UK Biobank study. Journal of Hepatology, 79(5), 1085–1095. https://doi.org/10.1016/j.jhep.2023.05.046
  64. Saeed, D., Reza, T., Shahzad, M. W., et al. (2023). Navigating the Crossroads: Understanding the Link Between Chronic Kidney Disease and Cardiovascular Health. Cureus, 15(12), e51362. https://doi.org/10.7759/cureus.51362
  65. Sehtman‐Shachar, D. R., Yanuv, I., Schechter, M., et al. (2024). Normoalbuminuriaβ€”is it normal? The association of urinary albumin within the "normoalbuminuric" range with adverse cardiovascular and mortality outcomes: A systematic review and meta‐analysis. Diabetes Obesity and Metabolism, 26(10), 4225–4240. https://doi.org/10.1111/dom.15752
  66. Sinning, C., Makarova, N., VΓΆlzke, H., et al. (2021). Association of glycated hemoglobin A1c levels with cardiovascular outcomes in the general population: results from the BiomarCaRE (Biomarker for Cardiovascular Risk Assessment in Europe) consortium. Cardiovascular Diabetology, 20(1). https://doi.org/10.1186/s12933-021-01413-4
  67. Sniderman, A. D., Thanassoulis, G., Glavinovic, T., et al. (2019). Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review. JAMA Cardiology, 4(12), 1287–1295. https://doi.org/10.1001/jamacardio.2019.3780
  68. Son, P., & Lewis, L. (2020). Hyperhomocysteinemia. PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK554408/
  69. Stone, N. J., Robinson, J. G., Lichtenstein, A. H., et al. (2014). 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. Journal of the American College of Cardiology, 63(25), 2889–2934. https://doi.org/10.1016/j.jacc.2013.11.002
  70. Tingle, R. (2022, June 6). 10 Type 2 Diabetes Risk Factors You May Not Know About. Rupa Health. https://www.rupahealth.com/post/what-causes-type-2-diabetes
  71. Valvular heart disease. Heart and Stroke Foundation of Canada. https://www.heartandstroke.ca/heart-disease/conditions/valvular-heart-disease
  72. Vinci, P., Di Girolamo, F. G., Panizon, E., et al. (2023). Lipoprotein(a) as a Risk Factor for Cardiovascular Diseases: Pathophysiology and Treatment Perspectives. International Journal of Environmental Research and Public Health, 20(18), 6721. https://doi.org/10.3390/ijerph20186721
  73. Weinberg, J. L. (2022, September 7). An Integrative Medicine Approach to Hypothyroidism. Rupa Health. https://www.rupahealth.com/post/understanding-hypothyroidism-and-how-to-treat-it-naturally
  74. Weinberg, J. L. (2023, February 7). A Functional Medicine Protocol for Hyperthyroidism. Rupa Health. https://www.rupahealth.com/post/5-functional-medicine-labs-that-can-assist-a-root-cause-treatment-for-hyperthyroidism
  75. Wilson, P. W. F., D’Agostino, R. B., Levy, D., et al. (1998). Prediction of Coronary Heart Disease Using Risk Factor Categories. Circulation, 97(18), 1837–1847. https://doi.org/10.1161/01.cir.97.18.1837
  76. World Health Organization. (2021, June 11). Cardiovascular Diseases (CVDs). World Health Organization. https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)
  77. Xia, F., Liu, G., Shi, Y., et al. (2015). Impact of microalbuminuria on incident coronary heart disease, cardiovascular and all-cause mortality: a meta-analysis of prospective studies. International Journal of Clinical and Experimental Medicine, 8(1), 1. https://pmc.ncbi.nlm.nih.gov/articles/PMC4358423/
  78. Yoshimura, H. (2023, March 30). The Importance of Running Comprehensive Metabolic Panel (CMP) on Your Patients. Rupa Health. https://www.rupahealth.com/post/the-importance-of-running-comprehensive-metabolic-panel-cmp-on-your-patients
  79. Your Heart and Diabetes. (2024, May 22). Centers for Disease Control and Prevention. https://www.cdc.gov/diabetes/diabetes-complications/diabetes-and-your-heart.html
  80. ZΓΊΓ±iga, D., Balasubramanian, S., Mehmood, K. T.,et al. (2024). Hypothyroidism and Cardiovascular Disease: A Review. Cureus, 16(1), e52512. https://doi.org/10.7759/cureus.52512
Subscribe to the Magazine for free to keep reading!
Subscribe for free to keep reading, If you are already subscribed, enter your email address to log back in.
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Are you a healthcare practitioner?
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
See All Magazine Articles
Trusted Source
Rupa Health
Medical Education Platform
Visit Source
American Cancer Society
Foundation for Cancer Research
Visit Source
National Library of Medicine
Government Authority
Visit Source
Journal of The American College of Radiology
Peer Reviewed Journal
Visit Source
National Cancer Institute
Government Authority
Visit Source
World Health Organization (WHO)
Government Authority
Visit Source
The Journal of Pediatrics
Peer Reviewed Journal
Visit Source
CDC
Government Authority
Visit Source
Office of Dietary Supplements
Government Authority
Visit Source
National Heart Lung and Blood Institute
Government Authority
Visit Source
National Institutes of Health
Government Authority
Visit Source
Clinical Infectious Diseases
Peer Reviewed Journal
Visit Source
Brain
Peer Reviewed Journal
Visit Source
The Journal of Rheumatology
Peer Reviewed Journal
Visit Source
Journal of the National Cancer Institute (JNCI)
Peer Reviewed Journal
Visit Source
Journal of Cardiovascular Magnetic Resonance
Peer Reviewed Journal
Visit Source
Hepatology
Peer Reviewed Journal
Visit Source
The American Journal of Clinical Nutrition
Peer Reviewed Journal
Visit Source
The Journal of Bone and Joint Surgery
Peer Reviewed Journal
Visit Source
Kidney International
Peer Reviewed Journal
Visit Source
The Journal of Allergy and Clinical Immunology
Peer Reviewed Journal
Visit Source
Annals of Surgery
Peer Reviewed Journal
Visit Source
Chest
Peer Reviewed Journal
Visit Source
The Journal of Neurology, Neurosurgery & Psychiatry
Peer Reviewed Journal
Visit Source
Blood
Peer Reviewed Journal
Visit Source
Gastroenterology
Peer Reviewed Journal
Visit Source
The American Journal of Respiratory and Critical Care Medicine
Peer Reviewed Journal
Visit Source
The American Journal of Psychiatry
Peer Reviewed Journal
Visit Source
Diabetes Care
Peer Reviewed Journal
Visit Source
The Journal of the American College of Cardiology (JACC)
Peer Reviewed Journal
Visit Source
The Journal of Clinical Oncology (JCO)
Peer Reviewed Journal
Visit Source
Journal of Clinical Investigation (JCI)
Peer Reviewed Journal
Visit Source
Circulation
Peer Reviewed Journal
Visit Source
JAMA Internal Medicine
Peer Reviewed Journal
Visit Source
PLOS Medicine
Peer Reviewed Journal
Visit Source
Annals of Internal Medicine
Peer Reviewed Journal
Visit Source
Nature Medicine
Peer Reviewed Journal
Visit Source
The BMJ (British Medical Journal)
Peer Reviewed Journal
Visit Source
The Lancet
Peer Reviewed Journal
Visit Source
Journal of the American Medical Association (JAMA)
Peer Reviewed Journal
Visit Source
Pubmed
Comprehensive biomedical database
Visit Source
Harvard
Educational/Medical Institution
Visit Source
Cleveland Clinic
Educational/Medical Institution
Visit Source
Mayo Clinic
Educational/Medical Institution
Visit Source
The New England Journal of Medicine (NEJM)
Peer Reviewed Journal
Visit Source
Johns Hopkins
Educational/Medical Institution
Visit Source